Temozolomide

Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocol INB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) was observed Median PFS in patients receiving multiple doses of INB-200 exceeds the historical median overall survival (mOS) of 14.6 months with the SOC Stupp protocol; notably, four patients remain alive and progression free for a median of over two years Company to host conference call with principal investigator at 8:30am EDT today. Use this link to participate, or access the listen-only version of the webcast here NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today announced new long-term clinical data from its fully enrolled Phase 1 trial of INB-200 in patients with newly diagnosed glioblastoma multiforme (GBM). The data were presented in an oral session on May 30th at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. “Half of the patients who received multiple doses remained progression free for greater than a year and a half, demonstrating functional recoveries, with several patients also having the ability to return to work. No new relapses have been reported since the last clinical update in October 2024” stated Burt Nabors, M.D., Division Director, Neuro-Oncology at the Heersink School of Medicine at the University of Alabama at Birmingham and Principal Investigator of the study. “These early data highlight the potential of repeated intracranial dosing of IN8bio’s gamma-delta T cells to extend mPFS in GBM, including in patients with chemotherapy-resistant tumors.” The Phase 1 results of INB-200 demonstrate that repeated dosing of IN8bio’s proprietary Drug Resistant Immunotherapy (DRI) – which utilizes genetically modified gamma-delta T cells delivered directly into the brain – in combination with SOC maintenance chemotherapy (temozolomide), led to an mPFS of 16.1 months. This represents an improvement of more than double (+9.2 months or +132.6%) the historical mPFS of 6.9 months under the SOC Stupp protocol. These mPFS results have already surpassed the historical mOS of 14.6 months associated with the SOC Stupp protocol alone. By comparison, a 2 to 3 month improvement in mPFS has historically been considered as clinically significant and the bar for approval by the Food and Drug Administration (FDA). Importantly, no dose-limiting toxicities (DLTs), CRS, or ICANS have been observed among patients treated with INB-200 (n=13). The majority of adverse events were Grade 1-2 and consistent with those typically associated with radiation and temozolomide. No treatment-related deaths have occurred. Highlights from the Clinical Data as of May 31, 2025: INB-200 Four patients (40%) who received repeated doses of INB-200 remain alive and progression free for a median of over two years, with three returning to work No additional relapses were observed since the last data update on October 18, 2024 Among patients who received multiple doses of INB-200, mPFS reached 16.1 months, compared to 6.9 months with SOC and 8.3 months for patients who received only a single dose of INB-200 Repeat dosing demonstrated no additional safety risks, with most side effects being mild and attributable to the SOC therapy 50% of patients receiving repeated doses remained progression-free >18 months versus 0% of patients who received a single dose INB-400 Data from our Phase 2 clinical trial of INB-400 in patients with newly diagnosed GBM, including three additional clinical sites, also show encouraging preliminary results: current mPFS is at 10.8 months. Additional updates expected late 2025 “Our goal is to achieve deeper responses and eliminate more cancer cells to ultimately extend the time patients can remain progression free and alive,” stated William Ho, CEO and cofounder of IN8bio. “The data presented at ASCO by Dr. Nabors speaks to the potential of IN8bio’s gamma-delta T cells to provide a game-changing immunotherapy for this dire and life-threatening cancer. We believe that INB-200 represents a novel direction in therapy for the treatment of solid tumor cancers like GBM. The complete data from our Phase 1 trial and supporting data from our Phase 2 trial represent the first time a gamma-delta T cell therapy has shown the potential to extend mPFS beyond historical benchmarks.” IN8bio’s approach delivers gamma-delta T cells directly to the tumor cavity after surgery, applying sustained immune pressure to eliminate residual cancer cells. The Company’s DRI technology is designed to treat newly diagnosed GBM by harnessing the natural tumor-targeting power of gamma-delta T cells and the sensitizing effects of chemotherapy. This approach aims to eliminate the chemo-resistant cancer and stem cells that often survive SOC treatment and can lead to relapse. Conference Call Details IN8bio will host a conference call and webcast featuring Dr. Burt Nabors, the Principal Investigator, today, Monday, June 2, 2025 at 8:30 am EDT to review the updated clinical data from the ASCO presentation. The webcast can be accessed by clicking this link and can also be accessed on the Events & Presentations page of the Company’s website. To participate in the live call, please register using this link. It is recommended that participants register at least 15 minutes in advance of the call. Once registered, participants will be informed of the dial-in number and will be provided a unique PIN. (1) Historical reported mPFS and mOS from Stupp Protocol (surgery, radiotherapy plus maintenance temozolomide); doi: 10.1056/NEJMoa043330 About IN8bio IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell-based immunotherapies for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-100, is focused on acute myeloid leukemia evaluating haplo-matched allogeneic γδ T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI γδ T cells, in combination with standard of care, for glioblastoma in its INB-200 and 400 programs, and advancing novel γδ T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit www.IN8bio.com. FORWARD LOOKING STATEMENTS This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the ability of repeated intracranial dosing of INB-200 to extend mPFS and improve mOS in patients with GBM, including those with chemotherapy-resistant tumors; INB-200’s ability to continue to be well-tolerated and show no serious toxicities beyond those typically observed with chemotherapy; INB-200’s ability to improve patient outcomes and allow patients to return to work; INB-400’s ability to improve mPFS; the ability of IN8bio’s DRI technology to offer a new way to treat newly-diagnosed GBM; gamma-delta T cells’ ability to eliminate chemo-resistant cancer and stem cells that often survive SOC treatment; INB-200’s potential as a novel direction in therapy for the treatment of solid tumor cancers like GBM; INB-200’s ability to improve outcomes in ways that enhance effectiveness of treatments without adding toxicity; IN8bio’s ability to achieve anticipated milestones, including the advancement of clinical development plans and receipt of regulatory approvals; and other statements that are not historical fact. IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as IN8bio’s ability to meet anticipated deadlines and milestones; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio’s product candidates; the risk that IN8bio may be unable to raise additional capital and could be forced to delay, further reduce or to explore other strategic options for certain of its development programs, or even terminate its operations; IN8bio’s ability to continue to operate as a going concern; the risk that IN8bio may not realize the intended benefits of its γδ-TCE platform or DeltEx platform; the availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio’s product candidates; the uncertainty of regulatory approvals to conduct trials or to market products; IN8bio’s reliance on third parties, including licensors and clinical research organizations; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section entitled “Risk Factors” in IN8bio’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 7, 2025, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Contacts: IN8bio, Inc. Patrick McCall 646.933.5603 pfmccall@IN8bio.com KKH Advisors Kimberly Ha 917.291.5744 kimberly.ha@kkhadvisors.com

芝加哥当地时间5月31日，2025年美国临床肿瘤学会（ASCO）年会正式开幕。作为国际肿瘤学领域最权威、最具影响力的年度盛会之一，全球顶尖专家齐聚于此，探讨、分享当前国际最前沿的肿瘤学科研成果和肿瘤治疗技术。恒瑞医药已连续15年携重磅研究成果参加ASCO年会。本届年会，恒瑞医药共有72项研究入选，其中创新药研究70项。包括4项口头报告（Oral）、5项快速口头报告（Rapid Oral）、27项壁报展示（Poster）、36项线上发表（Publication Only）[1]。研究成果涵盖消化系统肿瘤、乳腺癌、肺癌、妇科肿瘤、泌尿肿瘤、黑色素瘤、头颈肿瘤、肉瘤、鼻咽癌、血液肿瘤和硬纤维瘤等十余个肿瘤治疗领域。涉及的创新药包括8款已上市创新产品：注射用卡瑞利珠单抗（艾瑞卡®）、甲磺酸阿帕替尼片（艾坦®）、马来酸吡咯替尼片（艾瑞妮®）、羟乙磺酸达尔西利片（艾瑞康®）、阿得贝利单抗注射液（艾瑞利®）、氟唑帕利胶囊（艾瑞颐®）、注射用瑞康曲妥珠单抗（艾维达®，研发代号：SHR-A1811）、苹果酸法米替尼胶囊（艾比特®），以及7款未上市创新产品：抗PD-L1/TGF-βRII双抗瑞拉芙普-α（SHR-1701）、IL-15融合蛋白SHR-1501、双特异性抗体SHR-2017、全人源抗CTLA-4单克隆抗体SHR-8068、抗体偶联药物（ADC）SHR-1826、SHR-A1912、SHR-A2102。2类新药盐酸伊立替康脂质体注射液（II）（越优力®）及国内首仿药昂丹司琼口溶膜（艾其速®）各有1项研究入选。019项研究入选口头报告和快速口头报告凸显恒瑞硬核研发实力本次ASCO年会，恒瑞医药4项研究入选口头报告，5项研究入选快速口头报告，创新药成果涵盖多个前沿治疗领域，其学术价值与临床意义获得国际同行高度认可，不仅体现了公司在抗肿瘤新药研发领域的国际领先水平，更向全球学术界展示了中国医药创新的硬核实力。由中山大学肿瘤防治中心徐瑞华教授牵头，恒瑞自主研发的靶向c-MET ADC药物SHR-1826治疗实体瘤的一项I期临床研究成功入选口头报告[2]。该研究共纳入116例受试者，其中非小细胞肺癌（NSCLC）受试者72例。44%的受试者既往接受过≥3线的系统性抗肿瘤治疗。在58例可评估的NSCLC患者中，客观缓解率（ORR）达39.7%，疾病控制率（DCR）达94.8%。疗效覆盖不同c-MET表达水平患者。在所有的72例NSCLC中，中位无进展生存期（PFS）为6.8个月（95% CI，4.5–7.2）。该研究结果表明，SHR-1826在重度经治的实体瘤患者中展现出良好的安全性和耐受性；在NSCLC患者中表现出富有前景的抗肿瘤活性和持久缓解的潜力，且疗效不严格依赖于MET的高表达水平，有望进一步研究给广大患者带来新的福音。由上海交通大学附属胸科医院钟华教授、钟润波教授团队开展的一项Nectin-4靶向抗体偶联药物SHR-A2102治疗晚期实体瘤患者的I期研究成功入选口头报告[3]。该研究共纳入369例晚期实体瘤患者，中位年龄59岁；ECOG PS 1分85.6%；64.0%的患者接受过≥2线既往系统性治疗。在304例可评估疗效的患者中，ORR为35.2%（95% CI，29.8-40.9），DCR为84.2%（95% CI，79.6-88.1）。SHR-A2102在多种肿瘤类型中均表现出具有临床意义的抗肿瘤活性，不同亚型NSCLC的ORR为25%-43.5%；三阴性乳腺癌（TNBC）与HR阳性/HER2阴性乳腺癌ORR分别达56%与65%；头颈部鳞状细胞癌（HNSCC）ORR达50%。所有瘤种的DCR为73%-100%，显示出广泛的疾病控制能力。该研究结果表明，SHR-A2102在经多线治疗的实体瘤患者中展现出可控的安全性和广谱抗肿瘤活性。由复旦大学附属肿瘤医院季冬梅教授团队开展的一项瑞康曲妥珠单抗（SHR-A1811）治疗唾液腺癌的研究成功入选口头报告[4]。该研究共纳入33例晚期唾液腺癌患者，其中21例HER2过表达患者ORR为85.7%，DCR为100%；12例HER2低表达患者ORR为30.0%，DCR为100%。没有患者因治疗相关不良事件（TRAE）而停止治疗。该研究结果表明，SHR-A1811在HER2阳性和HER2低表达的晚期唾液腺癌中显示出有希望的疗效，并具有可控的安全性。由海军军医大学第二附属医院（上海长征医院)肖建如教授、杨诚教授团队开展的卡瑞利珠单抗联合阿帕替尼治疗晚期或难治性脊索瘤的单臂、开放标签、Ⅱ期研究成功入选口头报告[5]。该研究共有33例患者纳入疗效与安全性分析。根据RECIST 1.1，7例患者（21.2%，[95% CI，9.0-38.9]）达到部分缓解（PR），6个月DCR为85.2%（23/27），中位PFS为18.1个月（95% CI，11.0-28.5）。根据Choi标准，16例患者（48.5%，[95% CI，30.8-66.5]）达到PR，6个月DCR为77.7%（21/27），中位PFS为15.3个月（95% CI，10.6-NE）。研究结果表明，卡瑞利珠单抗联合阿帕替尼在脊索瘤的治疗中展现出良好的疗效与可控的安全性。02乳腺癌领域：吡咯替尼、达尔西利引领治疗新突破在乳腺癌领域，吡咯替尼、达尔西利、卡瑞利珠单抗、阿帕替尼、阿得贝利单抗、瑞康曲妥珠单抗（SHR-A1811）、SHR-2017，或产品间联合或联合化疗，共有19项研究入选（包括3项快速口头报道和7项壁报展示以及9项线上发表）。其中吡咯替尼占据7项、达尔西利占据6项，进一步巩固其在乳腺癌治疗中的地位。此外，瑞康曲妥珠单抗（SHR-A1811）、阿得贝利单抗相关研究入选快速口头报告，获得业内广泛关注。由复旦大学附属肿瘤医院邵志敏教授团队、天津市肿瘤医院郝继辉教授团队开展的DAWNA-A研究：达尔西利（Dalp）联合内分泌治疗（ET）用于HR+/HER2-早期乳腺癌的III期随机对照研究的首次中期分析结果成功入选快速口头报告[6]。该研究共纳入5274例患者，Dalp+ET组的侵袭性无病生存期（iDFS）显著优于安慰剂+ET组HR=0.56（95% CI，0.43–0.71），iDFS获益在各分层因素及基线亚组中表现一致；次要终点无病生存期（DFS）和远处无病生存期（DDFS）均支持Dalp+ET组的疗效优势。该研究结果表明，在ET治疗的基础上增加联合达尔西利能显著改善iDFS，且安全性可耐受。由河南省肿瘤医院闫敏教授团队牵头开展的瑞康曲妥珠单抗（SHR-A1811）治疗HER2阳性乳腺癌脑转移的最新结果成功入选快速口头报告[7]。该研究评估了SHR-A1811单药或联合贝伐珠单抗治疗HER2阳性乳腺癌脑转移（BCBM）的疗效与安全性。共入组58例患者，96.6%曾接受抗HER2治疗。截至2024年12月31日，确认的颅内ORR：单药组为84.4%，联合用药组为72.7%；两组DCR均为100%；单药组中位PFS为13.2个月，联合用药组尚未成熟。该研究结果表明，SHR-A1811单药或联合贝伐珠单抗均可获得较高的颅内缓解率。由复旦大学附属肿瘤医院张剑教授团队牵头开展的阿得贝利单抗联合贝伐珠单抗及顺铂/卡铂治疗合并脑转移的三阴性乳腺癌（TNBC）患者的II期临床研究成功入选快速口头报告[8]。研究共入组35例伴有活动性脑转移的TNBC患者，所有患者接受阿得贝利单抗、贝伐珠单抗，以及顺铂或卡铂的三联治疗方案。在ITT人群中，中枢神经系统客观缓解率（CNS-ORR）为77.1%，经确认的CNS-ORR为71.4%。在23例发生疾病进展的患者中，69.6%的患者首次进展发生在脑部。中位PFS为7.6个月（95% CI，5.7-11.5），而CNS-PFS为10个月（95% CI，7.4-12.6），中位OS为16个月（95% CI，11.7至未达到）。研究结果表明，阿得贝利单抗联合贝伐珠单抗及顺铂/卡铂展现出良好的颅内抗肿瘤活性，能够延长中枢神经系统无进展生存期（CNS-PFS）和OS，且具有良好的安全性。03消化系统肿瘤领域：卡瑞利珠单抗续写新篇章在消化系统肿瘤领域，卡瑞利珠单抗、阿帕替尼、阿得贝利单抗、SHR-8068等药物，共有30项研究入选（包括8项壁报和22项线上发表）。其中卡瑞利珠单抗占据21项，全面展现其显著特点与潜力，再次成为ASCO舞台焦点之一，续写国产PD-1抑制剂新篇章。此外，近年来在肺癌领域取得一系列突破的阿得贝利单抗也在积极探索新的适应症，本次ASCO大会分别有肝癌、胆管癌、胰腺癌等5项相关研究入选。这些新老药物前沿研究的不断出现，有望为消化系统肿瘤患者带来更多获益！04其他肿瘤领域：多点开花，彰显国际竞争力在肺癌、妇科肿瘤、淋巴瘤、膀胱癌、头颈肿瘤、黑色素瘤、肉瘤、鼻咽癌、脊索瘤、唾液腺癌、胸腺癌、硬纤维瘤、涎腺导管癌等其他多个疾病领域，卡瑞利珠单抗、阿帕替尼、阿得贝利单抗、吡咯替尼、达尔西利、氟唑帕利、法米替尼、瑞康曲妥珠单抗（SHR-A1811）、SHR-1501、瑞拉芙普-α（SHR-1701）、SHR-1826、SHR-A1912、SHR-A2102等抗肿瘤创新药相关研究一共入选了4项口头报告、2项快速口头报告、12项壁报展示和4项线上发表，彰显了恒瑞医药强劲的研发实力。此外，昂丹司琼口溶膜在防治化疗导致的恶心呕吐方面展现出了良好的疗效，本次ASCO年会有1项研究线上发表。由北京大学肿瘤医院宋玉琴教授团队牵头开展的“SHR-A1912联合治疗在B细胞非霍奇金淋巴瘤中的Ib/II期研究”入选大会快速口头报告[9]。剂量递增阶段的结果显示，1.8 mg/kg为SHR-A1912与R-GemOx联合治疗B细胞非霍奇金淋巴瘤的Ⅱ期试验推荐剂量（RP2D）。共有37例复发难治弥漫大B细胞淋巴瘤（DLBCL）患者接受了SHR-A1912 1.8 mg/kg联合R-GemOx方案（利妥昔单抗、吉西他滨、奥沙利铂）治疗（62.2%的受试者对上一线治疗难治，56.8%的受试者为原发难治），ORR为70.3%（95% CI，53.0-84.1），完全缓解率（CRR）为54.1%（95% CI，36.9-70.5），6个月持续缓解率为95.5%(95% CI，71.9-99.3)。研究结果表明，SHR-A1912联合R-GemOx展现出强大的抗肿瘤活性，有望成为复发难治DLBCL患者的新的治疗选择，进一步改善患者的预后。由北京大学肿瘤医院郭军教授团队开展的“卡瑞利珠单抗联合阿帕替尼、替莫唑胺新辅助治疗可切除的Ⅱ/Ⅲ期肢端黑色素瘤：CAP 03-NEO研究”成功入选大会快速口头报告[10]。在研究第一阶段接受手术的28例患者中，16例（57.1%）出现病理缓解，其中7例（25.0%）病理完全缓解（pCR），5例接近pCR，4例病理部分缓解（pPR）。此外，12例患者（42.9%）实现了主要病理缓解（MPR）。截止到2025年4月，中位无事件生存期（EFS）尚未到达，12个月的EFS率为77.6%（95% CI，56.7- 89.3%）。新辅助治疗并未增加手术并发症。该研究结果表明，卡瑞利珠单抗联合阿帕替尼、替莫唑胺新辅助治疗可切除的Ⅱ/Ⅲ期肢端黑色素瘤具有前景，支持该研究进入第二阶段以进一步评估其治疗Ⅲ期患者的疗效与安全性。《“健康中国2030”规划纲要》提出到2030年，要实现总体癌症5年生存率提高15%的战略目标。抗肿瘤药物是癌症患者控制和治疗疾病的重要希望。作为创新型国际化制药企业，恒瑞医药长期坚持“科技为本，为人类创造健康生活”的使命，针对肿瘤等严重威胁人类生命健康的疾病开展科研攻关，已上市的23款创新药中抗肿瘤创新药占比过半。公司另有90多个自主创新产品正在临床开发，近400多项临床试验在国内外开展。恒瑞医药连续15年携创新产品研究成果登上ASCO年会，体现了公司强大的抗肿瘤药物研发实力，也让国际肿瘤学界看到更多中国力量。未来，恒瑞医药将继续坚持“以患者为中心”的理念，力争研制出更多的新药、好药，服务“健康中国”，惠及全球患者。参考来源：[1]https://meetings.asco.org/abstracts-presentations/search?query=*&q=2025%20ASCO%20Annual%20Meeting[2]Phase 1 study of SHR-1826, a c-MET–directed antibody-drug-conjugate (ADC), in advanced solid tumors. ASCO 2025：Oral abstract 106.[3]Phase 1 trial of SHR-A2102, a nectin-4–directed antibody drug conjugate (ADC), in advanced solid tumors. ASCO 2025：Oral abstract 107.[4]SHR-A1811 in HER2-expressing salivary gland cancers: Preliminary efficacy and safety results. ASCO 2025：Oral abstract 6006.[5]Camrelizumab plus apatinib in patients with advanced or refractory chordoma: A single-arm, open-label, phase 2 trial. ASCO 2025：Oral abstract 11503.[6]Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2– early breast cancer (BC): The randomized, phase 3, DAWNA-A trial. ASCO 2025：Rapid Oral abstract 515.[7]HER2-ADC trastuzumab rezetecan (SHR-A1811) in HER2-positive breast cancer with brain metastases: Update results from REIN trial. ASCO 2025：Rapid Oral abstract 1017.[8]A phase II clinical study of adebrelimab and bevacizumab combined with cisplatin/carboplatin in triple-negative breast cancer patients with brain metastases. ASCO 2025：Rapid Oral abstract 1018.[9]CD79b-targeted antibody-drug conjugate (ADC) SHR-A1912 in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL): Data from a phase 1b/2 study. ASCO 2025：Rapid Oral abstract 7013.[10]Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II/III acral melanoma: The CAP 03-NEO trial. ASCO 2025：Rapid Oral abstract 9512.声明：1.本新闻旨在分享学术前沿动态，仅供医疗卫生专业人士基于学术目的参阅，非广告用途。2.恒瑞医药不对任何药品和/或适应症作推荐。3.本新闻中涉及的信息仅供参考，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。撰稿：肿瘤中央医学事务部排版：程梦真责编：李玉莹往期精选|  研发创新  |恒瑞创新药瑞坦宁®获批，用于预防成人高度致吐性化疗引起的急性和迟发性恶心呕吐|  国际化  |恒瑞医药再次与德国默克集团达成合作，推进辅助生殖领域口服GnRH拮抗剂商业化落地恒瑞医药与默沙东就Lp(a)抑制剂HRS-5346签订独家许可协议|  重磅奖项  |喜报！恒瑞医药荣获2023年度国家科技进步奖恒瑞医药连续六年入选全球制药企业50强榜单！|  社会公益  |“健康中国行·重走长征路”项目启动仪式圆满举行！恒瑞提供公益支持，助力健康中国恒瑞医药集团向中国扶贫基金会捐赠3000万设立“健康帮扶基金”